



Review

Oxygen-Ozone Therapy for Reducing Pro-Inflammatory Cytokines Serum Levels in Musculoskeletal and Temporomandibular Disorders: A Comprehensive Review

Alessandro de Sire ^{1,*} , Nicola Marotta ¹ , Martina Ferrillo ² , Francesco Agostini ³, Cristiano Sconza ^{4,5} , Lorenzo Lippi ⁶ , Stefano Respizzi ⁴, Amerigo Giudice ² , Marco Invernizzi ^{6,7} and Antonio Ammendolia ¹

¹ Physical Medicine and Rehabilitation Unit, Department of Medical and Surgical Sciences, University of Catanzaro “Magna Graecia”, 88100 Catanzaro, Italy; nicola.marotta@unicz.it (N.M.); ammendolia@unicz.it (A.A.)

² Department of Health Sciences, University of Catanzaro “Magna Graecia”, 88100 Catanzaro, Italy; martinaferrillo@hotmail.it (M.F.); a.giudice@unicz.it (A.G.)

³ Department of Anatomy, Histology, Forensic Medicine and Orthopedics, Sapienza University, 00185 Rome, Italy; francesco.agostini@uniroma1.it

⁴ IRCCS Humanitas Research Center, Via Manzoni 56, 20089 Rozzano, Italy; cristiano.sconza@humanitas.it (C.S.); stefano.respizzi@humanitas.it (S.R.)

⁵ Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Italy

⁶ Physical and Rehabilitative Medicine, Department of Health Sciences, University of Eastern Piedmont “A. Avogadro”, 28100 Novara, Italy; lorenzolippi.mt@gmail.com (L.L.); marco.invernizzi@med.uniupo.it (M.I.)

⁷ Translational Medicine, Dipartimento Attività Integrate Ricerca e Innovazione (DAIRI), Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy

* Correspondence: alessandro.desire@unicz.it; Tel.: +39-0961712819



Citation: de Sire, A.; Marotta, N.; Ferrillo, M.; Agostini, F.; Sconza, C.; Lippi, L.; Respizzi, S.; Giudice, A.; Invernizzi, M.; Ammendolia, A. Oxygen-Ozone Therapy for Reducing Pro-Inflammatory Cytokines Serum Levels in Musculoskeletal and Temporomandibular Disorders: A Comprehensive Review. *Int. J. Mol. Sci.* **2022**, *23*, 2528. <https://doi.org/10.3390/ijms23052528>

Academic Editor: Elizabeth W. Bradley

Received: 27 January 2022

Accepted: 23 February 2022

Published: 25 February 2022

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: To date, the application of oxygen-ozone (O₂O₃) therapy has significantly increased in the common clinical practice in several pathological conditions. However, beyond the favorable clinical effects, the biochemical effects of O₂O₃ are still far from being understood. This comprehensive review aimed at investigating the state of the art about the effects of O₂O₃ therapy on pro-inflammatory cytokines serum levels as a modulator of oxidative stress in patients with musculoskeletal and temporomandibular disorders (TMD). The efficacy of O₂O₃ therapy could be related to the moderate oxidative stress modulation produced by the interaction of ozone with biological components. More in detail, O₂O₃ therapy is widely used as an adjuvant therapeutic option in several pathological conditions characterized by chronic inflammatory processes and immune overactivation. In this context, most musculoskeletal and temporomandibular disorders (TMD) share these two pathophysiological processes. Despite the paucity of in vivo studies, this comprehensive review suggests that O₂O₃ therapy might reduce serum levels of interleukin 6 in patients with TMD, low back pain, knee osteoarthritis and rheumatic diseases with a concrete and measurable interaction with the inflammatory pathway. However, to date, further studies are needed to clarify the effects of this promising therapy on inflammatory mediators and their clinical implications.

Keywords: ozone; oxygen-ozone therapy; musculoskeletal disorders; temporomandibular disorders; pain management; rehabilitation; low back pain; osteoarthritis; inflammation

1. Introduction

Ozone gas (O₃) was discovered in 1840, and its expansion into the medical field has given rise to compelling research in the recent decades to validate its clinical value [1]. Despite some controversies, several papers [2–11] have proposed relevant medical features, including bactericidal and virucidal effects, inflammatory modulation and circulatory stimulation, with considerable applications in several medical fields such as wound healing,

ischemic disorders, infections, and chronic inflammatory conditions such as musculoskeletal disorders.

The function of O_3 shares similarities with that of a prodrug, as it is modified upon reacting with molecules to develop more active substrates, thus prompting an endogenous cascade of reactions [12]. On the other hand, it is hard to classify O_3 as merely a prodrug, due to its power to directly interact with phospholipids, lipoproteins, bacteria envelopes and viral capsids. Therefore, O_3 is considered one of the most powerful oxidizing molecules in nature, although, at high concentrations, it rapidly decomposes into ordinary oxygen [13]. O_3 rapidly reacts with water and polyunsaturated fatty acids (PUFA) and in human fluids and tissues, producing, respectively, hydrogen peroxide (H_2O_2) and a combination of lipid ozonation products (LOP), mainly composed by 4-HNE (from omega-6 PUFA) and 4-HHE (trans-4 hydroxy-2-hexenal from omega-3 PUFA) [13]. In this context, H_2O_2 , acting as an ozone messenger, is considered as the fundamental reactive oxygen species (ROS). However, other ROS have been identified as products of ozone reactions, such as superoxide ions and hydroxyl radical (OH^-) [14]. Hence, given the role of signal transduction, the previous concept that ROS are always harmful has recently been revised and replaced by the latest evidence describing ROS as mediators of the host defense and immune responses [15].

Cytokines are undoubtedly involved in these processes and the proinflammatory cytokines tumor necrosis factor- α (TNF- α), interleukin-1 (IL-1), macrophage migration inhibitory factor (MIF) play a pivotal role [16,17]. Cytokines have been considered encouraging biomarkers and clinical targets in rheumatic and oncologic therapies, but, to date, anti-cytokine-based therapeutic approaches such as the use of anti-TNF antibodies, soluble TNF receptors or IL-1 receptor antagonists have failed to ascertain a clear clinical advantage [18,19]. In addition, some antioxidants and ROS scavengers could exert a protecting effort against endotoxic shock in rodents by hampering TNF- α .

Thus, it has been demonstrated that ozone–oxygen (O_2O_3) mixture might play a key role as a microbiocidal agent compared to the rich bactericidal activity of NO, serving as a modulator of several inflammatory processes in vivo [20,21]. O_2O_3 exhibits various effects on the immune system, such as the modulation of macrophages' phagocytic activity, which provides the first-line defense against bacteria and toxins [22].

In this scenario, O_2O_3 concentrations should be set to a specific range to ensure safety; however, patients might present a sensation of heaviness at the injection site that spontaneously decreases in a few minutes. On the contrary, other adverse effects might be related to an incorrect administration technique, including vagal crisis, pain, hematoma in the injection site, local infections, and even death [23–25].

Moreover, it has been demonstrated that low amounts of ozone increased endogenous antioxidant pathways, entangling glutathione (GSH), superoxide dismutase (SOD) and catalase (CAT), and preparing the host to face ROS-mediated physiopathological circumstances. The ozone, through oxidative preconditioning, protects tissues from ROS-related damage, promoting the antioxidant–prooxidant balance and the concomitant preservation of the cell redox state [26–28]. Therefore, we could hypothesize that O_2O_3 mixture could enhance proinflammatory cytokine modulation [29].

Musculoskeletal disorders are considered as a common cause of pain and functional disability, predicting a burden that will further increase due to the aging of the population [30–34]. They include all inflammatory and rheumatic diseases affecting the osteoarticular system such as osteoarthritis (OA), but also low back pain and temporomandibular disorders [35–39].

O_2O_3 therapy has assumed the role of an adjuvant therapeutic approach in various pathological disorders characterized by chronic inflammatory processes and immune hyper activation, and most musculoskeletal disorders share these two pathophysiological scenarios [40]. In this context, several authors presented a practical function of O_2O_3 in the management of low back pain (LBP) with promising perspectives, as a minimally invasive approach, for the conservative therapies of disc herniation or protrusion and in case of failed back surgery syndrome [41–47]. At the same time, a recent systematic review [48]

documented that knee pain could be decreased after O_2O_3 intra-articular management in patients affected by knee osteoarthritis (KOA). Likewise, tendon disorders are another conceivable focus for O_2O_3 therapy, and a recent randomized controlled trial (RCT) evaluated the usefulness of O_2O_3 therapy in patients with shoulder impingement, indicating that it might be assumed an intriguing alternative intervention in case of contraindication to corticosteroids [49]. Moreover, O_2O_3 injective treatment reported positive results after O_2O_3 injection in patients with lateral chronic epicondylitis not responding to conventional therapy [50]. Lastly, favourable developments have been documented even in rheumatic diseases, where O_2O_3 rectal insufflations or autohemotherapy seemed to reveal a profitable safety profile, promoting positive prospective in fibromyalgia [51].

A common denominator of these widespread pathologies is the low-grade inflammatory profile, with a similar serum pattern of inflammatory mediators [52–54]. This concept has been recently investigated for the development of more specific and sensitive methods for early diagnosis and follow-up, starting from a detailed and targeted phenotypic characterization of musculoskeletal and temporomandibular disorders [55].

To date, although it has been suggested that O_2O_3 therapy could be an effective analgesic treatment, its specific anti-inflammatory effects in terms of serum levels of cytokines modifications are controversial.

Several other musculoskeletal diseases might take advantage of the O_2O_3 therapy that is commonly used in the PRM clinical practice. However, only a few papers have investigated the effects of O_2O_3 therapy on other musculoskeletal disorders leading to disability (i.e., cervical pain, tendinopathies, and fibromyalgia). Moreover, it should be considered that O_2O_3 therapy is commonly used in the clinical practice as anti-inflammatory and analgesic therapeutic option for temporomandibular disorders (TMD) and general musculoskeletal and rheumatic diseases (Figure 1).




Figure 1. Main clinical targets for oxygen-ozone therapy as anti-inflammatory and analgesic treatment.

Therefore, in the present comprehensive review, we aimed to investigate the state of the art about the effects of O_2O_3 therapy on pro-inflammatory cytokines serum levels as a modulator of oxidative stress in patients with TMD and musculoskeletal disorders.

2. Oxygen-Ozone as Anti-Inflammatory Therapy

O₃ is composed of three oxygen atoms with a cyclic structure [56]. It is generated for medical use from pure oxygen which passes through a high voltage gradient (5–13 mV) following the reaction:



The result is a gas mixture composed of not less than 95% oxygen and not more than 5% O₃. O₃ is 1.6 times denser and 10 times more soluble in water than oxygen. It should be considered that O₃ is the most powerful oxidant after fluorine and persulfate, although it is not a radical molecule. It is an unstable gas that cannot be stored and should be used right away as it has a half-life of 40 min at 20 °C. Despite the heterogeneous and current applications in the medical field, the biochemical effects of O₂O₃ are still difficult to understand, even if its properties and chemical characteristics seem to suggest some of its positive clinical effects [40,44,57–59].

Like any other gas, O₃ physically dissolves in pure water according to Henry's law in relation to temperature, pressure, and ozone concentration. Unlike O₂, O₃ reacts immediately with the water present in the tissues. O₃ reacts with polyunsaturated fatty acids (PUFA), antioxidants such as ascorbic and uric acid, and thiol compounds with -SH groups (cysteine, reduced glutathione-GSH and albumin). Depending on the dose of O₃ administered, enzymes, carbohydrates, DNA and RNA may also be involved in the process. These compounds undergo oxidation, acting as electron donors [56]. O₃, interacting with water and PUFA, present in the tissues, leads to the formation of hydrogen peroxide (H₂O₂), a fundamental reactive oxygen species (ROS) which acts as an ozone messenger, and other lipid ozonation products (LOPs) [33–35].

H₂O₂ is a non-radical oxidant capable of acting as an O₃ messenger to elicit numerous biological and therapeutic effects. The fact that ROS are always harmful is a concept widely revised in the literature as, in physiological quantities, they are considered mediators of host defense and immune responses. Moreover, they have an extremely short duration (seconds), but by virtue of their reactivity, they could damage cellular components if their generation is not well calibrated. The composition of ROS in the plasma is very rapid and is accompanied by a transient (15–20 min for the recycling of oxidized compounds) and modest decrease in the antioxidant capacity. H₂O₂ diffuses very easily from plasma to cells (intracellular gradient 1/10 of the plasma one) and represents an important biological stimulus. In tissues, the moderate oxidative stress of ROS is canceled by endogenous radical scavengers (superoxide dismutase, glutathione peroxidase, catalase, NADPH quinone-oxidoreductase, etc.) [60,61].

An excess of ROS can in fact lead to the formation of toxic compounds such as peroxyxynitrite (O₅NOO₂) and hypochlorite anion (ClO₂). Furthermore, the presence of traces of Fe⁺⁺ should be avoided because, in the presence of hydrogen peroxide, they catalyze the formation of the most reactive OH, through the Fenton reaction (hydroxyl radical) [56].

LOPs (lipoperoxides-LOO, alkoxy radicals-LO, lipohydroperoxides-LOOH, iso-prostane and alkenes (4-hydroxy-2,3-transnonenal-HNE and malonyldialdehyde-MDA)) are signal molecules of acute oxidative stress and they cause an upregulation of antioxidant enzymes, such as superoxide dismutase (SOD), GSH-peroxidase (GSH-Px), GSH-reductase (GSH-Rd) and catalase (CAT), which play a key role in antioxidant defense. They also induce oxidative stress proteins, one of which is heme-oxygenase I (HO-1 or HSP-32), which degrades the heme molecule. Being toxic and much more stable in vitro than ROS, they must be generated in very low concentrations and metabolized by GSH-transferase (GSH-Tr) and aldehyde dehydrogenase [56].

Therefore, following the administration of O₃ the formation of ROS and LOP takes place and, due to their chemical diversity, they act in two different phases. ROS behave as early and short-acting messengers, while on the other hand, LOPs act as late and long-lasting messengers. Thus, they spread in different tissues and bind in small quantities to cell receptors, thus minimizing their toxicity [56].

Small and repeated oxidative stresses might induce the activation of the transcriptional factor mediating nuclear factor-erythroid 2-related factor 2 (Nrf2), a domain involved in the transcription of antioxidant response elements (ARE) and usually bound to protein 1 associated with ECH Kelchlike (Keap-1), thus creating an inactive complex in the intracellular space. A mild oxidative stress can therefore favor the release of Nrf2 from this complex and its migration into the nucleus, where it would favor the transcription of different AREs on the DNA, binding to the Maf protein [62,63].

Therefore, through repeated mild oxidative stresses, O₃ could induce the upregulation of Nrf2, conditioning human cells to transcribe different AREs, stimulating a better response to pathological radical stress, common in most chronic inflammatory diseases [12].

Several antioxidant enzymes reach a higher level of concentration in response to the production of AREs, such as superoxide dismutase, catalase (CAT), glutathione-transferase (GST), heme oxygenase (HO)-1, heat shock proteins, glutathione peroxidase and quinone-oxidoreductase. These enzymes play a “scavenger role” of free radicals. Based on the redox state of the cell and the amount of O₂O₃ administered, we can observe different effects. For example, O₂O₃ overexpresses HO-1 or NO-producing 32 kPa heat shock proteins (Hsp34) and, furthermore, Hsp70 expression levels are in turn upregulated by O₂O₃, which is related to HO-1. Heme is enzymatically degraded by HO-1 and can be toxic depending on free iron, amount produced and biliverdin. Biliverdin is a nitrosative and oxidative stress neutralizer based on the ability to interact with reactive nitrogen and NO species. The response to thermal shock provides a cytoprotective state during an inflammatory process, aging and neurodegenerative disorders. HO isoforms appear to be regulators of cellular redox homeostasis, functioning as dynamic sensors of its oxidative stress. O₂O₃ may play a role in regulating the proinflammatory and anti-inflammatory effects of prostaglandin formation, which is similar in nature to NO [40].

Furthermore, Nrf2 appears to play an important role in the intracellular signaling pathways of inflammation. Indeed, the activation of the Nrf2-antioxidant signal could attenuate a key regulator of the inflammatory response and muscle atrophy (NF- κ B), and furthermore, the literature suggests that the inflammatory response could be directly down-regulated by suppression of crucial inflammatory mediators and cytokines (IL-6, IL-8 and TNF- α) [64–66].

Low doses of O₃ could therefore play a role in the regulation of prostaglandin synthesis, in the release of bradykinin and in the increase of macrophage and leukocyte secretions. It is widely accepted that pain is a common symptom related to the inflammatory process and O₂O₃ therapy could play a key role not only in the management of inflammation, but also in nociceptive perception and modulation. As for the analgesic use of O₂O₃, after the administration of O₂O₃, an increase in antioxidant molecules (serotonin and endogenous opioids) has been demonstrated, which would induce pain relief by stimulating the antinociceptive pathways [3,6,67–69].

Therefore, the effect of O₃ mimics an acute oxidative stress that, if properly balanced, is not harmful, but is able to elicit positive biological responses and reverse chronic oxidative stress (degenerative process, aging, etc.) This hypothesis about ozone and oxidative stress modulation could be better defined as a “real non-toxic therapeutic shock able to restore homeostasis” [56,70,71].

3. Oxygen-Ozone and Back Pain

Little evidence is available in literature about the effect of O₂O₃ injections in patients with low back pain due to lumbar disc herniation [72,73]. Although the fluoroscopy or tomography guide requirement could limit the feasibility of this therapy in conventional rehabilitation settings, positive effects were reported in comparison with other interventions such as steroid intraforaminal injection [74]. On the contrary, intramuscular-paravertebral O₂O₃ therapy seems to be safe, reliable, and effective to reduce pain in patients affected by LBP not responding to anti-inflammatory/analgesic drugs [75,76].

The O₂O₃ might exert its action combining mechanical and anti-inflammatory effects, breaking glycosaminoglycan chains in the nucleus pulposus, decreasing their capability to retain water, thus lowering the size of the herniated position, and allowing to relieve the hernial conflict [22,77]. A reduction in disk volume is the result of all these events. In a study conducted by Andreula et al. [78], five histologic disk specimens were removed during surgical microdiscectomy, providing intradiscal injections of O₃ at 27 µg/mL, and reporting the nucleus pulposus fibrillary matrix dehydration, regression, and collagen fibers revealing. Parallely, O₂O₃ might also influence the inflammatory cascade by modulating the breakdown of arachidonic acid into prostaglandins and facilitating the fibroblastic action, stimulating the deposition of collagen and the initiation of the repairing process at the tissue level [57].

Around the disc protrusion, inflammatory mediators prompted by granulation tissue are known to attract histiocytes, fibroblasts, and chondrocytes that can produce interleukin-1α (IL-1α), interleukin-6 (IL-6), and TNF-α; these cytokines induce the prostaglandin E2 pathway, which causes pain or increases the sensitivity of the nerve roots to other algogenic substances, such as bradykinin [79]. In vivo, local injection of medical ozone would increase the concentrations of TNF-α, IL1β, and IFN-γ around the disc, suggesting that the contact of medical ozone with the disc damages the extracellular matrix, resulting in shrinkage and decompression of the surrounding neurons. This might proceed probably together with the decrease in lactic acid and inflammatory cytokines, resulting in the decrease of low back pain and sciatica [80].

Furthermore, this disk shrinkage can enhance local microcirculation and increase oxygen supply by decreasing venous stasis caused by disk vessel compression. The O₂O₃ therapy might have analgesic and anti-inflammatory effects in treating disk herniation due to the neutralization of proinflammatory cytokines by boosting the surge of antagonists' release [25].

When a disc degeneration leads to disc herniation, the adjacent nervous system structures, such as the nerve roots, or the dorsal root ganglion can be affected, causing neuropathic pain of mechanical or biochemical origin [81]. Moreover, other spinal structures are damaged, including facet joints, ligaments, and muscles, which can also become pain generators [82]. However, the peripheral sensitization should be avoided by O₂O₃ mediators, since recent evidence suggests that ozonized low-density lipoprotein inhibits NFκB and IL-1 receptor-associated kinase 1 (IRAK-1) signaling [83]. At the same time, the oxidation of IL, IL receptors, or nuclear factors might block COX-2 expression [84]. Clinically, Niu et al. showed that low concentrations of medical ozone (20 and 40 µg/mL) can reduce the serum IL-6, IgG, and IgM expression, presenting as analgesic and anti-inflammatory effects; while high concentrations of medical ozone (60 µg/mL) increase the serum IL-6, IgG, and IgM expression, presenting as pain and pro-inflammatory effects. Thus, the medical ozone concentration of 40 µg/mL seemed to report the optimal treatment efficacy [85].

In conclusion, ozone therapy might reduce the autoimmune inflammatory reaction and, consequently, pain due to radiculopathy, after the exposure of the nucleus pulposus to the immune system [22]. Intramuscular O₂O₃ therapy is a safe and widely used procedure in the common clinical practice but these results could be only achieved starting from strict eligibility criteria in patient selection and trained and experienced physicians to perform the procedure. Nevertheless, further research must provide evidence for a correct balance between O₂O₃ dosage and inflammatory mediators' expression.

4. Oxygen-Ozone and Osteoarthritis

OA is a widespread musculoskeletal disease and a leading cause of chronic disability [86]. Conservative estimates state that up to 240 million people worldwide suffer from it [87]. OA is not merely a degenerative disease, considering that both mechanical and inflammatory factors are attributed to its pathophysiology [88–90]. The paradigm of OA is changing from the non-inflammatory theory of “wear and tear” to the hypothesis of

“chronic low-grade inflammation” [91,92]. Long-time exposure to chronic low-grade inflammation and imbalance in oxidant-antioxidant systems is involved in OA pathogenesis and progression by compromising the complex network of signaling pathways that regulate cartilage and subchondral bone homeostasis [93,94].

A crucial role in this process might be played by inflammatory cytokines released by chondrocytes (IL-1 β , IL-6, IL-8, IL-17, TNF- α , IFN- γ), promoting the catabolism of cartilage and subchondral bone [93,94]. Under normal conditions, these catabolic factors are in equilibrium with anabolic factors that include anti-inflammatory cytokines (IL-4, IL-10) and anabolic cytokines (TGF- β , IGF-1, FGF-18, and PDGF) [95–97]. Inflammatory and catabolic factors produce an imbalance that leads a healthy joint to develop OA [97].

As a result, clinical research is looking for immunomodulatory treatments that can act on inflammation to reduce the progression of OA and stimulate the synthesis of anabolic factors [48]. Among these, O₂O₃ represents a promising treatment option for its ability to modulate inflammation, promote cartilage growth, and joint repair mechanisms [48,61,98]. O₃ might influence the modulation of inflammation through different mediators and signaling pathways [4,99,100]. In synovial fluid, O₃ decreases the production of pro-inflammatory cytokines, particularly IL-6, IL-1 β , and TNF- α , which are responsible for cartilage degradation [101]. This effect of ozone has been observed and demonstrated in several studies in animal models of knee OA (KOA), rheumatoid arthritis, and in models of ischemia/reperfusion, e.g., in the reduction of neuropathic pain [3,98,102].

A recent *in vivo* study on intra-articular O₂O₃ injection treatment in patients with KOA has shown that O₃ is capable of reducing serum levels of IL-6 [91]. This is particularly interesting because IL-6 is produced by IL-1 β and TNF- α , two important inflammatory cytokines that appear to play a key role in the initiation and development of OA [103]. IL-1 is responsible for cartilage destruction whereas TNF- α activates the inflammatory process [91]. The authors also demonstrated that O₃ could be capable of improving serum IGF-1 levels. IGF-1 is a growth factor with important properties in reducing inflammation and stimulating cell growth, differentiation, and tissue repair [104].

Hashemi et al. obtained similar results showing that treatment with intra-articular injections of ozone in patients with KOA induces a significant reduction in serum levels of inflammatory cytokines at 1, 2, and 6 months after the procedure [101]. This result is also greater at 2 and 6 months compared with patients treated with steroid injections. Notably, IL-1b and TNF- α serum levels significantly decreased in the ozone group compared with the steroid group. The authors’ hypothesis is that ozone is likely to have a more stable anti-inflammatory effect than steroids. Although the steroid has a robust anti-inflammatory action against inflammatory cytokines, this effect in cartilage tissue was shorter than ozone. The biochemical findings of this study are also confirmed by the clinical outcomes; in fact, patients treated with ozone demonstrated a more lasting improvement in pain and disability compared to steroid injection.

These results represent *in vivo* confirmation of previous *in vitro* experiments focusing on the ability of ozone to reduce serum levels of pro-inflammatory cytokines by stimulating the production of anti-inflammatory cytokines and anabolic chemokines. These intriguing biological effects could be strictly connected to the clinical improvements observed in these patients.

Inflammatory cytokines can also increase the production of ROS which can activate the NF-K β pathway leading to accelerating cartilage matrix disintegration and apoptosis [105–109]. Ozone has been observed to decrease the NF-K β pathway and enhance the Nrf2 (Nuclear factor erythroid 2-related factor 2) pathway, which is involved in the generation of antioxidant response elements (AREs) such as superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), and hemoxygenase-1(HO-1) [110,111]. The activated NF-K β pathway could lead to a downstream cascade of other proinflammatory cytokines giving rise to a vicious circle that perpetuates the chronic inflammatory process [112]. Ozone inhibition of NF-K β activation can reduce the degradation of the cartilage matrix and initiation of the apoptotic pathway, thus supporting cell survival [108] (Figure 2).




Figure 2. Ozone (O₃) intracellular and intranuclear pathways involved in inflammation and oxidative stress.

Although injured or damaged articular cartilage remains one of the most difficult tissues to treat [113], it has been recently highlighted that the ozone could provide promising results as a safe and effective treatment in patients with KOA from both a biochemical and clinical perspective [3,114–121].

5. Oxygen-Ozone and Rheumatic Diseases

Rheumatoid arthritis (RA) is the most frequent pathology associated with chronic joint inflammation, a genetic degenerative disease that initially affects extremity joints and is characterized by a chronic inflammatory state that distorts and demolishes articular cartilage and expands connective tissue fibrosis, leading to cell destruction and subchondral bone deterioration. It has been estimated that about 1% of the world population suffers from this disorder [122]. O₂O₃ therapy effectively decreased inflammation with a down-regulation of pro-inflammatory cytokines and an up-regulation of IL-10 anti-inflammatory cytokine [123]. Rajesh and collaborators investigated the temporal expression of cytokines during the initial phase of an experimental model of arthritic inflammation and revealed that interferon-gamma (IFN-γ) participates in inflammatory process modulation [124]. The O₃ has also been shown to effectively increase the clinical response of methotrexate (MTX) in patients with rheumatoid arthritis induced by PG/PS. The combination therapy diminishes inflammation through reduction of IL-1B and TNF-α and decreases oxidative stress by reducing hydrogen and preventing damage to proteins and lipids [125].

In this scenario, O₂O₃ therapy seems to play a positive role in several inflammatory conditions due to its bacteriostatic, oxidative stress, immune and epigenetic modulation. Compared with topical ozone administration, systematic ozone therapy has apparent advantages in enhancing metabolism, blood hypercoagulability, angiosclerosis, insomnia, and rejuvenation of the body [2,126]. Thus, psoriasis vulgaris is a chronic immune-mediated inflammatory cutaneous disease characterized by red, itchy, and scaly skin patches. Patients typically suffer disfiguration, disability, and associated comorbidities [112]. Zeng et al. indicated that short-term O₂O₃ therapy seemed to attenuate psoriatic disease severity lowering

the level of blood lipids and up-streaming PPAR- γ level in CD4 T cells, considering that the PPAR- γ expression is commonly reduced in CD4 T cells in psoriasis [127].

Systemic sclerosis (SSc) is an immune-mediated rheumatic disease, characterized by skin and visceral organs fibrosis and vasculopathy [128,129]. Carpal tunnel syndrome (CTS) is one of the most common entrapment disorders in general and the most recurring peripheral nervous system involvement in SSc [130,131]. Elawamy et al. demonstrated that both intracarpal ozone or methylprednisolone reported advantageous impacts upon CTS in people with SSC; nonetheless, ozone relieves pain, enhances the hand functioning, decreases the duration and frequency of Raynaud's attacks, declines the size of ulceration, and improves median nerve conduction study over the 6-month follow-up [132]. Rascaroli et al. found slight improvements in sensory and motor parameters after ozone therapy, and Bahrami et al. showed improvement of median sensory nerve action potential latency, compared to the pre-treatment level in both groups (one group treated with wrist volar splint alone, the other group treated with ozone injection and splint) [133–136]. The nature of the fibrotic expression in SSc people with CTS seemed to be significantly associated with gene upstream for Col1 and Col3, TGF- β , and SMAD3 in CTS fibroblasts [137,138]. These studies, focusing on TGF- β signaling inhibition in CTS, reported that therapies targeted for the TGF- β pathway might eventually have utility for the prevention and treatment of CTS, as well as the anti-fibrotic effect of relaxin [137,138].

Gout disease is one of the most frequent causes of inflammatory arthritis in adults and is chronic disorder associated with self-limiting acute gout attacks (gout flare), caused by the accretion of monosodium urate (MSU) depositions in joints and surrounding soft tissue and bursa [139–141]. Acute episodes of gout disease are one of the most influential reasons for unfavourable health-related quality of life [139–141]. In a rat model, ozone therapy indicated a decrease in the degree of edematous ankle swelling, pro-inflammatory cytokines, lipid peroxidation, the nucleotide-binding oligomerization domain-like receptor containing pyrin domain 3 (NLRP3), procaspase-1, caspase-1, interleukin-1 β synovial tissue levels with an enhancement of antioxidant defence system [142]. In other murine models, Bilge et al. demonstrated that ozone therapy raises the levels of antioxidant enzymes, including oxidative shock proteins (hemo-oxygenase-1), Interleukin 4 and Interleukin 10, TGF- β , NO endorphin, adrenocorticotrophic hormone (ACTH), and cortisol levels [141].

In conclusion, the positive effect of ozone treatment sustained by its bidirectional regulation of immunity are present also in rheumatic diseases patients. These positive effects could be caused by a O₂O₃-related massive production of inflammatory modulation cytokines by immune cells.

6. Oxygen-Ozone and Temporomandibular Disorders

Temporomandibular disorders (TMD) represent heterogeneous musculoskeletal disorders, defined as a multifactorial set of signs and symptoms involving masticatory muscles of the stomatognathic system, temporomandibular joint (TMJ), or both [143].

According to the Diagnostic Criteria for TMD (DC/TMD) Axis I, TMD could be divided in muscle disorders (including myofascial pain) or intra-articular disorders (including disc displacement with or without reduction, arthralgia, and arthritis) [144,145].

TMD are the second most common musculoskeletal disorders, affecting approximately 90% of the general population [146–148]. Indeed, TMD are the first most common cause of pain of non-dental origin in the maxillofacial region [149], with an incidence rate of 3.9% per annum [150].

Main clinical symptoms are pain and limited jaw range of motion, often accompanied by decrease in the maximal interincisal opening, muscle or joint tenderness on palpation, joint sounds, and otologic complaints (e.g., tinnitus, vertigo, or ear fullness) [151,152]. These signs and symptoms could lead to discomfort or difficulty in performing activities of daily living, such as eating, chewing, talking, swallowing, yawning, causing disability with a significantly reduced quality of life [153–155].

The etiology has been accepted as multifactorial, and parafunctional habits, clenching of teeth, grinding, as well as psychosocial issues, including anxiety depression are generally believed to contribute to the development or perpetuation of the pain complaints [156–159].

In response to this imbalance of the masticatory system, cytokines such as $\text{TNF}\alpha$, IL-1, IL-6 and IL-8 are released within TMJ [160], thus promoting the release of proteinases and stimulating the expression of degrading enzymes and inflammatory mediators; all this mechanism could lead to a TMJ inflammation and bone and cartilage degradation [161]. Other cytokines and metallo-proteinases (MMPs) could be involved in the inflammatory process, including interferon-gamma ($\text{IFN-}\gamma$), prostaglandin E2 (PGE2), IL-17, MMP-2, MMP-9, aggrecanase-1 and aggrecanase-2 [162–165].

More in detail, both immune and non-immune cells could release $\text{TNF-}\alpha$ (e.g., macrophages, synoviocytes, and neurons associated with the trigeminal ganglion), causing TMJ inflammation and pain in myofascial TMD patients [165]. Ulmner et al. [166] characterized and quantified the synovial tissue cytokines and related the result to the diagnoses of disc displacement with or without reduction. Results of this study showed that bone morphogenetic protein (BMP) type 2 and 4, epidermal growth factor (EGF), eotaxin, granulocyte-colony stimulating factor (G-CSF), IL-1 β , IL-7, IL-8, IL-10, macrophage inflammatory protein (MIP) 1 β , $\text{TNF-}\alpha$ and $\text{TNF-}\beta$ had significantly higher concentrations in patients with disc displacement without reduction. In 2021, Son et al. [167] investigated the relationship between long-term clinical characteristics and different cytokine and autoimmunity levels in young female TMD patients according to pain disability. The subjects included in the study were classified in high and low disability groups, according to the Graded Chronic Pain Scale (GCPS). The authors showed that IL-8 and IgG levels were significantly higher in the high disability group ($p = 0.047$ and 0.005 , respectively).

Several conservative treatments have been used for reducing TMD-related pain, including occlusal splint devices [168,169], behavioral therapies [170], manual therapy [171], laser therapy [172], transcutaneous electrical nerve stimulation (TENS) [173], dry needling [173]. In this context, O_2O_3 therapy [152,174–176] might be considered as a promising new treatment to reduce TMD pain, although the mechanism of action should still be adequately investigated [177]. Probably, O_2O_3 might effectively decrease inflammation with a down-regulation of pro-inflammatory cytokines and an up-regulation of IL-10 anti-inflammatory cytokine [123].

In the context of muscle-related TMD, Celakil et al. [178] recently conducted a double-blind randomized clinical trial in order to evaluate the efficacy of ozone therapy compared to placebo. Topical gaseous ozone therapy was applied to the muscles of 20 participants three times per week for 10 min for 2 weeks, with a significantly lower VAS score than placebo group after treatment ($p = 0.040$). Moreover, the pressure pain threshold of the temporal muscle, masseter muscle, and TMJ lateral pole were significantly higher in the ozone group ($p = 0.035$; $p = 0.007$; $p = 0.012$, respectively). The same authors also compared the bio-oxidative ozone therapy to occlusal splints therapy in patients affected by both muscle and articular TMD disorders [135,175,179], showing that both therapies were effective in the improvement of mandibular movements and VAS scores. However, evaluating the effects in terms of PPT measurement of the temporal and masseter, their results indicated that occlusal splint treatment produced better results than ozone application ($p = 0.046$; $p = 0.024$, respectively). In the context of intra-articular TMD, Daif et al. compared the effects of TMJ ozone injections to medication therapy in TMD patients with disc displacement with reduction [180]. In the ozone group, each joint received 2 mL ozone–oxygen mixture (10 $\mu\text{g}/\text{mL}$) injections, 2 times per week for 3 weeks, whereas patients in the second group received nonsteroidal anti-inflammatory drugs and muscle relaxants showing. Results of this study showed that 87% of the patients who received ozone gas injections into the superior joint space either completely recovered (37%) or improved (50%), whereas in the medication group, only 33% of the patients showed an improvement in their clinical dysfunction indexes.

To date, the precise mechanism underpinning the positive effects of O₂O₃ therapy in TMD patients are far from being understood. However, O₃ decreases the production of pro-inflammatory cytokines, particularly IL-6, IL-1 β , and TNF- α , which are responsible for cartilage degradation in the synovial fluid [101]. Thus, when injected into a joint capsule, O₂O₃ could be able to stimulate the intrinsic fibroblastic joint repairing abilities and to promote new cartilage growth as well as reducing inflammation [180,181]. Therefore, ozone therapy is a not-invasive, fast, and comfortable treatment modality that seems to be effective in the pain management framework in TMD. This could have positive implications for these patients in improving mandibular function, although the precise role of O₂O₃ on serum levels of pro-inflammatory cytokines should be better investigated.

7. Conclusions

In conclusion, this comprehensive review describes the impact of O₂O₃ therapy on serum cytokine levels in different settings and conditions. As previously described, musculoskeletal and rheumatological disorders include several pathological conditions characterized by different and complex therapeutic approaches. In this scenario, O₂O₃ therapy remains a promising conservative and minimally invasive intervention that improves pain symptoms and patients' quality of life. To date, evidence suggests a role of O₂O₃ therapy in IL-6 and IL-10 serum level modulation, although the precise epigenetic mechanism remains controversial. Therefore, further high-quality studies are needed to fully understand the molecular, epigenetic, and biochemical effects of O₂O₃ and its therapeutic implications.

Author Contributions: Conceptualization, A.d.S.; methodology, A.d.S.; formal analysis, N.M., M.F., F.A., C.S. and L.L.; data curation, A.d.S., S.R., A.G., M.I. and A.A.; writing—original draft preparation, A.d.S. and N.M.; writing—review and editing, M.I. and A.A.; visualization, M.F., F.A., C.S., L.L., S.R. and A.G.; supervision, A.d.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Di Meo, S.; Venditti, P. Evolution of the Knowledge of Free Radicals and Other Oxidants. *Oxid. Med. Cell. Longev.* **2020**, *2020*, 9829176. [[CrossRef](#)] [[PubMed](#)]
2. Akkawi, I. Ozone therapy for musculoskeletal disorders: Current concepts. *Acta Biomed.* **2020**, *91*, e2020191. [[CrossRef](#)]
3. de Sire, A.; Stagno, D.; Minetto, M.A.; Cisari, C.; Baricich, A.; Invernizzi, M. Long-term effects of intra-articular oxygen-ozone therapy versus hyaluronic acid in older people affected by knee osteoarthritis: A randomized single-blind extension study. *J. Back Musculoskelet. Rehabil.* **2020**, *33*, 347–354. [[CrossRef](#)]
4. Apuzzo, D.; Giotti, C.; Pasqualetti, P.; Ferrazza, P.; Soldati, P.; Zucco, G.M. An observational retrospective/horizontal study to compare oxygen-ozone therapy and/or global postural re-education in complicated chronic low back pain. *Funct. Neurol.* **2014**, *29*, 31–39. [[CrossRef](#)] [[PubMed](#)]
5. Galiè, M.; Covi, V.; Tabaracci, G.; Malatesta, M. The role of Nrf2 in the antioxidant cellular response to medical ozone exposure. *Int. J. Mol. Sci.* **2019**, *20*, 4009. [[CrossRef](#)]
6. Paoloni, M.; Di Sante, L.; Cacchio, A.; Apuzzo, D.; Marotta, S.; Razzano, M.; Franzini, M.; Santilli, V. Intramuscular oxygen-ozone therapy in the treatment of acute back pain with lumbar disc herniation: A multicenter, randomized, double-blind, clinical trial of active and simulated lumbar paravertebral injection. *Spine* **2009**, *34*, 1337–1344. [[CrossRef](#)]
7. Baranova, I.V.; Bezsmertnyi, Y.A.; Bezsmertnaya, H.V.; Postovitenko, K.P.; Iliuk, I.A.; Gumeniuk, A.F. Analgetic effect of ozone therapy: Myths of reality? *Pol. Ann. Med.* **2020**, *27*, 62–67. [[CrossRef](#)]
8. Rajkumar, K.V.; Jeevitha, M.; Sangeetha, S. Knowledge and awareness of ozone therapy among dental professionals. *Int. J. Res. Pharm. Sci.* **2020**, *11*, 303–307. [[CrossRef](#)]
9. Fitzpatrick, E.; Holland, O.J.; Vanderlelie, J.J. Ozone therapy for the treatment of chronic wounds: A systematic review. *Int. Wound J.* **2018**, *15*, 633–644. [[CrossRef](#)]
10. Sanjeevi, J.; Santhosh Kumar, M.P. Ozone therapy in dentistry. *Drug Invent. Today* **2019**, *12*, 154–157. [[CrossRef](#)]

11. Masan, J.; Sramka, M.; Rabarova, D. The possibilities of using the effects of ozone therapy in neurology. *Neuroendocrinol. Lett.* **2021**, *42*, 13–21. [[PubMed](#)]
12. Smith, N.; Wilson, A.; Gandhi, J.; Vatsia, S.; Khan, S. Ozone therapy: An overview of pharmacodynamics, current research, and clinical utility. *Med. Gas Res.* **2017**, *7*, 212–219. [[CrossRef](#)] [[PubMed](#)]
13. Rajendran, L.; Knölker, H.J.; Simons, K. Subcellular targeting strategies for drug design and delivery. *Nat. Rev. Drug Discov.* **2010**, *9*, 29–42. [[CrossRef](#)] [[PubMed](#)]
14. Li, Y.R.; Trush, M. Defining ROS in Biology and Medicine. *React. Oxyg. Species* **2016**, *1*, 9–21. [[CrossRef](#)]
15. Dumas, A.; Knaus, U.G. Raising the ‘Good’ Oxidants for Immune Protection. *Front. Immunol.* **2021**, *12*, 42. [[CrossRef](#)]
16. Liu, M.; Xie, Z.; Sun, G.; Chen, L.; Qi, D.; Zhang, H.; Xiong, J.; Furey, A.; Rahman, P.; Lei, G.; et al. Macrophage migration inhibitory factor may play a protective role in osteoarthritis. *Arthritis Res. Ther.* **2021**, *23*, 59. [[CrossRef](#)]
17. Kany, S.; Vollrath, J.T.; Relja, B. Cytokines in inflammatory disease. *Int. J. Mol. Sci.* **2019**, *20*, 6008. [[CrossRef](#)]
18. Marques, R.E.; Guabiraba, R.; Russo, R.C.; Teixeira, M.M. Targeting CCL5 in inflammation. *Expert Opin. Ther. Targets* **2013**, *17*, 1439–1460. [[CrossRef](#)]
19. Gubernatorova, E.O.; Namakanova, O.A.; Gorshkova, E.A.; Medvedovskaya, A.D.; Nedospasov, S.A.; Drutskaya, M.S. Novel Anti-Cytokine Strategies for Prevention and Treatment of Respiratory Allergic Diseases. *Front. Immunol.* **2021**, *12*, 1842. [[CrossRef](#)]
20. Malferrari, M.; Beconi, M.; Rapino, S. Electrochemical monitoring of reactive oxygen/nitrogen species and redox balance in living cells. *Anal. Bioanal. Chem.* **2019**, *411*, 4365–4374. [[CrossRef](#)]
21. Vaneev, A.N.; Gorelkin, P.V.; Garanina, A.S.; Lopatukhina, H.V.; Vodopyanov, S.S.; Alova, A.V.; Ryabaya, O.O.; Akasov, R.A.; Zhang, Y.; Novak, P.; et al. In Vitro and in Vivo Electrochemical Measurement of Reactive Oxygen Species after Treatment with Anticancer Drugs. *Anal. Chem.* **2020**, *92*, 8010–8014. [[CrossRef](#)] [[PubMed](#)]
22. de lo Erario, M.A.; Croce, E.; Moviglia Brandolino, M.T.; Moviglia, G.; Grangeat, A.M. Ozone as modulator of resorption and inflammatory response in extruded nucleus pulposus herniation. Revising concepts. *Int. J. Mol. Sci.* **2021**, *22*, 9946. [[CrossRef](#)] [[PubMed](#)]
23. Santos, G.M.; Pacheco, R.L.; Bussadori, S.K.; Santos, E.M.; Riera, R.; de Oliveira Cruz Latorraca, C.; Mota, P.; Benavent Caldas Bellotto, E.F.; Martimbianco, A.L.C. Effectiveness and Safety of Ozone Therapy in Dental Caries Treatment: Systematic Review and Meta-analysis. *J. Evid. Based. Dent. Pract.* **2020**, *20*, 101472. [[CrossRef](#)] [[PubMed](#)]
24. Del Valle, L.G.; Guerra, M.M.D.; Carballo-Reyes, A.L.; Márquez, J.A.S.; Fernández, O.E.L.; Betancourt, F.F.; Zamora-Rodríguez, Z.; García, L.A.F.; Iznaga, R.S.; Casanueva, R.M.; et al. Observance of adverse reactions and analysis of biosafety compliance in the rectal application of ozone therapy in COVID-19 Cuban patients with acute infection or convalescent. *J. Pharm. Pharmacogn. Res.* **2021**, *9*, 465–473.
25. Bocci, V. The Clinical Application of Ozonotherapy. In *OZONE*; Springer: Dordrecht, The Netherlands, 2010.
26. Sharifi-Rad, M.; Anil Kumar, N.V.; Zucca, P.; Varoni, E.M.; Dini, L.; Panzarini, E.; Rajkovic, J.; Tsouh Fokou, P.V.; Azzini, E.; Peluso, I.; et al. Lifestyle, Oxidative Stress, and Antioxidants: Back and Forth in the Pathophysiology of Chronic Diseases. *Front. Physiol.* **2020**, *11*, 694. [[CrossRef](#)] [[PubMed](#)]
27. Rao, X.; Zhong, J.; Brook, R.D.; Rajagopalan, S. Effect of Particulate Matter Air Pollution on Cardiovascular Oxidative Stress Pathways. *Antioxid. Redox Signal.* **2018**, *28*, 797–818. [[CrossRef](#)]
28. Hasanuzzaman, M.; Bhuyan, M.H.M.B.; Zulfiqar, F.; Raza, A.; Mohsin, S.M.; Al Mahmud, J.; Fujita, M.; Fotopoulos, V. Reactive oxygen species and antioxidant defense in plants under abiotic stress: Revisiting the crucial role of a universal defense regulator. *Antioxidants* **2020**, *9*, 681. [[CrossRef](#)]
29. Franzini, M.; Valdenassi, L.; Ricevuti, G.; Chirumbolo, S.; Depfenhart, M.; Bertossi, D.; Tirelli, U. Oxygen-ozone (O₂-O₃) immunocutaneous therapy for patients with COVID-19. Preliminary evidence reported. *Int. Immunopharmacol.* **2020**, *88*, 106879. [[CrossRef](#)]
30. Ruiz-Fernández, C.; Francisco, V.; Pino, J.; Mera, A.; González-Gay, M.A.; Gómez, R.; Lago, F.; Gualillo, O. Molecular relationships among obesity, inflammation and intervertebral disc degeneration: Are adipokines the common link? *Int. J. Mol. Sci.* **2019**, *20*, 2030. [[CrossRef](#)]
31. Farrell, S.F.; de Zoete, R.M.J.; Cabot, P.J.; Sterling, M. Systemic inflammatory markers in neck pain: A systematic review with meta-analysis. *Eur. J. Pain* **2020**, *24*, 1666–1686. [[CrossRef](#)]
32. Blüher, M. Inflammation: Between obesity, diabetes and exercise. *Diabetologie* **2021**, *17*, 141–148. [[CrossRef](#)]
33. Paradis, M.E.; Couture, P.; Giguère, I.; Marin, J.; Vohl, M.C.; Lamarche, B. Impact of systemic enzyme supplementation on low-grade inflammation in humans. *PharmaNutrition* **2015**, *3*, 83–88. [[CrossRef](#)]
34. Mobasheri, A.; Henrotin, Y. Biomarkers of (osteo)arthritis. *Biomarkers* **2015**, *20*, 513–518. [[CrossRef](#)] [[PubMed](#)]
35. Ogura, T.; Suzuki, M.; Sakuma, Y.; Yamauchi, K.; Orita, S.; Miyagi, M.; Ishikawa, T.; Kamoda, H.; Oikawa, Y.; Kanisawa, I.; et al. Differences in levels of inflammatory mediators in meniscal and synovial tissue of patients with meniscal lesions. *J. Exp. Orthop.* **2016**, *3*, 7. [[CrossRef](#)]
36. Rahmati, M.; Mobasheri, A.; Mozafari, M. Inflammatory mediators in osteoarthritis: A critical review of the state-of-the-art, current prospects, and future challenges. *Bone* **2016**, *85*, 81–90. [[CrossRef](#)]
37. Yucel-Lindberg, T.; Båge, T. Inflammatory mediators in the pathogenesis of periodontitis. *Expert Rev. Mol. Med.* **2013**, *15*, e7. [[CrossRef](#)]

38. Tang, C.; Chen, Y.; Huang, J.; Zhao, K.; Chen, X.; Yin, Z.; Heng, B.C.; Chen, W.; Shen, W. The roles of inflammatory mediators and immunocytes in tendinopathy. *J. Orthop. Transl.* **2018**, *14*, 23–33. [[CrossRef](#)]
39. Abdulkhaleq, L.A.; Assi, M.A.; Abdullah, R.; Zamri-Saad, M.; Taufiq-Yap, Y.H.; Hezmee, M.N.M. The crucial roles of inflammatory mediators in inflammation: A review. *Vet. World* **2018**, *11*, 627–635. [[CrossRef](#)]
40. Seyam, O.; Smith, N.L.; Reid, I.; Gandhi, J.; Jiang, W.; Khan, S.A. Clinical utility of ozone therapy for musculoskeletal disorders. *Med. Gas Res.* **2018**, *8*, 103–110.
41. Bonetti, M.; Zambello, A.; Princiotta, C.; Pellicanò, G.; Della Gatta, L.; Muto, M. Non-discogenic low back pain treated with oxygen-ozone: Outcome in selected applications. *J. Biol. Regul. Homeost. Agents* **2020**, *34*, 21–30.
42. Han, H.J.; Kim, J.Y.; Jang, H.Y.; Lee, B.; Yoon, J.H.; Jang, S.K.; Choi, S.H.; Jeong, S.W. Fluoroscopic-guided intradiscal oxygen-ozone injection therapy for thoracolumbar intervertebral disc herniations in dogs. *In Vivo* **2007**, *21*, 609–613. [[PubMed](#)]
43. Migliorini, F.; Maffulli, N.; Eschweiler, J.; Bestch, M.; Tingart, M.; Baroncini, A. Ozone injection therapy for intervertebral disc herniation. *Br. Med. Bull.* **2020**, *136*, 88–106. [[CrossRef](#)]
44. Melchionda, D.; Milillo, P.; Manente, G.; Stoppino, L.; Macarini, L. Treatment of radiculopathies: A study of efficacy and tollerability of paravertebral oxygen-ozone injections compared with pharmacological anti-inflammatory treatment. *J. Biol. Regul. Homeost. Agents* **2012**, *26*, 467–474. [[PubMed](#)]
45. Dal Fior, S.; Gaido, C.; Carnino, I.; Gamna, F.; Busso, C.; Massazza, G.; Minetto, M.A. Clinical predictors of response to ozone therapy for treatment of discogenic and non-discogenic low back pain. *J. Biol. Regul. Homeost. Agents* **2020**, *34*, 1223–1228. [[CrossRef](#)] [[PubMed](#)]
46. de Magalhães, F.N.O.; Soares, S.C.; Torres, J.M.; Ungaretti, A.; Cacciaccaro, M.F.; Teixeira, M.J.; Fonoff, E.T. Effects of ozone applied by spinal endoscopy in patients with chronic pain related to failed back surgery syndrome: A pilot study. *Neuropsychiatr. Dis. Treat.* **2013**, *9*, 1759–1766. [[CrossRef](#)]
47. Barbosa, D.C.; Ângelos, J.S.; De Macena, G.M.J.; De Oliveira Magalhães, F.N.; Fonoff, E.T. Effects of ozone on the pain and disability in patients with failed back surgery syndrome. *Rev. Assoc. Med. Bras.* **2017**, *63*, 355–360. [[CrossRef](#)]
48. Sconza, C.; Respizzi, S.; Virelli, L.; Vandenbulcke, F.; Iacono, F.; Kon, E.; Di Matteo, B. Oxygen–Ozone Therapy for the Treatment of Knee Osteoarthritis: A Systematic Review of Randomized Controlled Trials. *Arthrosc. J. Arthrosc. Relat. Surg.* **2020**, *36*, 277–286. [[CrossRef](#)]
49. Travagli, V.; Zanardi, I.; Bernini, P.; Nepi, S.; Tenori, L.; Bocci, V. Effects of ozone blood treatment on the metabolite profile of human blood. *Int. J. Toxicol.* **2010**, *29*, 165–174. [[CrossRef](#)]
50. Gökhan Ulusoy, R.; Bilge, A.; Öztürk, Ö. Comparison of corticosteroid injection and ozone injection for relief of pain in chronic lateral epicondylitis. *Acta Orthop. Belg.* **2019**, *85*, 317–324.
51. Moreno-Fernández, A.M.; Macías-García, L.; Valverde-Moreno, R.; Ortiz, T.; Fernández-Rodríguez, A.; Moliní-Estrada, A.; De-Miguel, M. Autohemotherapy with ozone as a possible effective treatment for Fibromyalgia. *Acta Reumatol. Port.* **2019**, *44*, 244–249.
52. Storheim, K.; Zwart, J.A. Musculoskeletal disorders and the Global Burden of Disease study. *Ann. Rheum. Dis.* **2014**, *73*, 949–950. [[CrossRef](#)] [[PubMed](#)]
53. Minetto, M.A.; Giannini, A.; McConnell, R.; Busso, C.; Torre, G.; Massazza, G. Common musculoskeletal disorders in the elderly: The star triad. *J. Clin. Med.* **2020**, *9*, 1216. [[CrossRef](#)] [[PubMed](#)]
54. Mendes, A.F.; Cruz, M.T.; Gualillo, O. Editorial: The Physiology of Inflammation—The Final Common Pathway to Disease. *Front. Physiol.* **2018**, *9*, 1741. [[CrossRef](#)]
55. Berenbaum, F.; Walker, C. Osteoarthritis and inflammation: A serious disease with overlapping phenotypic patterns. *Postgrad. Med.* **2020**, *132*, 377–384. [[CrossRef](#)]
56. Bocci, V.A. Scientific and medical aspects of ozone therapy. State of the art. *Arch. Med. Res.* **2006**, *37*, 425–435. [[CrossRef](#)] [[PubMed](#)]
57. de Sire, A.; Agostini, F.; Lippi, L.; Mangone, M.; Marchese, S.; Cisari, C.; Bernetti, A.; Invernizzi, M. Oxygen–ozone therapy in the rehabilitation field: State of the art on mechanisms of action, safety and effectiveness in patients with musculoskeletal disorders. *Biomolecules* **2021**, *11*, 356. [[CrossRef](#)]
58. Bernetti, A.; Agostini, F.; de Sire, A.; Mangone, M.; Tognolo, L.; Di Cesare, A.; Ruiu, P.; Paolucci, T.; Invernizzi, M.; Paoloni, M. Neuropathic pain and rehabilitation: A systematic review of international guidelines. *Diagnostics* **2021**, *11*, 74. [[CrossRef](#)]
59. de Sire, A.; Baricich, A.; Minetto, M.A.; Cisari, C.; Invernizzi, M. Low back pain related to a sacral insufficiency fracture: Role of paravertebral oxygen-ozone therapy in a paradigmatic case of nociplastic pain. *Funct. Neurol.* **2019**, *34*, 119–122.
60. İnal, M.; Dokumacioglu, A.; Özcelik, E.; Ucar, O. The effects of ozone therapy and coenzyme Q 10 combination on oxidative stress markers in healthy subjects. *Ir. J. Med. Sci.* **2011**, *180*, 703–707. [[CrossRef](#)]
61. Manoto, S.L.; Maepa, M.J.; Motaung, S.K. Medical ozone therapy as a potential treatment modality for regeneration of damaged articular cartilage in osteoarthritis. *Saudi J. Biol. Sci.* **2018**, *25*, 672–679. [[CrossRef](#)]
62. Sagai, M.; Bocci, V. Mechanisms of action involved in ozone therapy: Is healing induced via a mild oxidative stress? *Med. Gas Res.* **2011**, *1*, 1–18. [[CrossRef](#)]
63. Thi Xuan, N.; Hai Ha, N.; Thanh Chung, D. Vitamin E Attenuates FasL-Induced Apoptotic Death of Dendritic Cells Through PI3K Signalling. *VNU J. Sci. Med. Pharm. Sci.* **2021**, *37*, 4268. [[CrossRef](#)]

64. Mourkioti, F.; Kratsios, P.; Luedde, T.; Song, Y.H.; Delafontaine, P.; Adami, R.; Parente, V.; Bottinelli, R.; Pasparakis, M.; Rosenthal, N. Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. *J. Clin. Investig.* **2006**, *116*, 2945–2954. [[CrossRef](#)] [[PubMed](#)]
65. Xie, T.; Yan, W.; Lou, J.; Chen, X. Effect of ozone on vascular endothelial growth factor (VEGF) and related inflammatory cytokines in rats with diabetic retinopathy. *Genet. Mol. Res.* **2016**, *15*, 15027558. [[CrossRef](#)]
66. Peralta, C.; León, O.; Xaus, C.; Prats, N.; Jalil, E.; Planell, E.S.; Puig-Parellada, P.; Gelpi, E.; Roselló-Catafau, J. Protective effect of ozone treatment on the injury associated with hepatic ischemia-reperfusion: Antioxidant-prooxidant balance. *Free Radic. Res.* **1999**, *31*, 191–196. [[CrossRef](#)] [[PubMed](#)]
67. Peralta, C.; Xaus, C.; Bartrons, R.; Leon, O.S.; Gelpi, E.; Rosello-Catafau, J. Effect of ozone treatment on reactive oxygen species and adenosine production during hepatic ischemia-reperfusion. *Free Radic. Res.* **2000**, *33*, 595–605. [[CrossRef](#)] [[PubMed](#)]
68. Paolucci, T.; Cardarola, A.; Colonnelli, P.; Ferracuti, G.; Gonnella, R.; Murgia, M.; Santilli, V.; Paoloni, M.; Bernetti, A.; Agostini, F.; et al. Give me a kiss! An integrative rehabilitative training program with motor imagery and mirror therapy for recovery of facial palsy. *Eur. J. Phys. Rehabil. Med.* **2020**, *56*, 58–67. [[CrossRef](#)]
69. Longas Vélez, B.P. Ozone therapy, a supplement for patients with fibromyalgia. *Rev. Esp. Ozonoter.* **2014**, *4*, 39–49.
70. Paolucci, T.; Agostini, F.; Bernetti, A.; Paoloni, M.; Mangone, M.; Santilli, V.; Pezzi, L.; Bellomo, R.G.; Saggini, R. Integration of focal vibration and intra-articular oxygen-ozone therapy in rehabilitation of painful knee osteoarthritis. *J. Int. Med. Res.* **2021**, *49*, 6705. [[CrossRef](#)] [[PubMed](#)]
71. Agostini, F.; Bernetti, A.; Di Giacomo, G.; Viva, M.G.; Paoloni, M.; Mangone, M.; Santilli, V.; Masiero, S. Rehabilitative Good Practices in the Treatment of Sarcopenia. *Am. J. Phys. Med. Rehabil.* **2020**, *100*, 280–287. [[CrossRef](#)]
72. Biazzo, A.; Corriero, A.S.; Confalonieri, N. Intramuscular oxygen-ozone therapy in the treatment of low back pain. *Acta Biomed* **2018**, *89*, 41–46. [[CrossRef](#)]
73. Cantele, F.; Tognolo, L.; Caneva, F.; Formaggio, E.; Copetti, V.; Venturin, A.; Caregnato, A.; Masiero, S. Influence of pain-related psychological factors on therapeutic outcomes in patients with chronic low back pain after oxygen-ozone treatment: A case-series. *Eur. J. Transl. Myol.* **2021**, *31*, 9906. [[CrossRef](#)] [[PubMed](#)]
74. Wong, O.; Zhang, G.; Matthews, H.; Skalski, M.; Asadi, H.; Laloo, S.; Kurda, D. Image-guided spinal injection for pain management. *J. Med. Imaging Radiat. Oncol.* **2021**, *66*, 79–91. [[CrossRef](#)]
75. Alyan, S.; Zaghlol, R.; Mustafa, S.A. Efficacy of combined paravertebral ozone (O₂O₃) therapy with physiotherapy in patients with chronic mechanical low back pain. *Egypt. Rheumatol. Rehabil.* **2018**, *45*, 106–111. [[CrossRef](#)]
76. Sucuoğlu, H.; Soydaş, N. Does paravertebral ozone injection have efficacy as an additional treatment for acute lumbar disc herniation? A randomized, double-blind, placebo-controlled study. *J. Back Musculoskelet. Rehabil.* **2021**, *34*, 725–733. [[CrossRef](#)]
77. Cunha, C.; Teixeira, G.Q.; Machado, C.; Pereira, C.L.; Ferreira, J.R.; Molinos, M.; Santos, S.G.; Barbosa, M.A.; Goncalves, R.M. Modulation of the In Vivo Inflammatory Response by Pro- Versus Anti-Inflammatory Intervertebral Disc Treatments. *Int. J. Mol. Sci.* **2020**, *21*, 1730. [[CrossRef](#)]
78. Andreula, C.F.; Simonetti, L.; de Santis, F.; Agati, R.; Ricci, R.; Leonardi, M. Minimally Invasive Oxygen-Ozone Therapy for Lumbar Disk Herniation. *Am. J. Neuroradiol.* **2003**, *24*, 996–1000.
79. De Geer, C.M. Cytokine Involvement in Biological Inflammation Related to Degenerative Disorders of the Intervertebral Disk: A Narrative Review. *J. Chiropr. Med.* **2018**, *17*, 54–62. [[CrossRef](#)]
80. Li, J.-K.; Nie, L.; Zhao, Y.-P.; Zhang, Y.-Q.; Wang, X.; Wang, S.-S.; Liu, Y.; Zhao, H.; Cheng, L. IL-17 mediates inflammatory reactions via p38/c-Fos and JNK/c-Jun activation in an AP-1-dependent manner in human nucleus pulposus cells. *J. Transl. Med.* **2016**, *14*, 77. [[CrossRef](#)] [[PubMed](#)]
81. Brisby, H. Pathology and possible mechanisms of nervous system response to disc degeneration. *J. Bone Jt. Surg. Ser. A* **2006**, *88*, 68–71.
82. Perolat, R.; Kastler, A.; Nicot, B.; Pellat, J.-M.; Tahon, F.; Attye, A.; Heck, O.; Boubagra, K.; Grand, S.; Krainik, A. Facet joint syndrome: From diagnosis to interventional management. *Insights Imaging* **2018**, *9*, 773–789. [[CrossRef](#)]
83. Barnabei, L.; Laplantine, E.; Mbongo, W.; Rieux-Laucat, F.; Weil, R. NF-κB: At the Borders of Autoimmunity and Inflammation. *Front. Immunol.* **2021**, *2021*, 3169. [[CrossRef](#)]
84. Wang, B.; Wu, L.; Chen, J.; Dong, L.; Chen, C.; Wen, Z.; Hu, J.; Fleming, I.; Wang, D.W. Metabolism pathways of arachidonic acids: Mechanisms and potential therapeutic targets. *Signal Transduct. Target. Ther.* **2021**, *6*, 94. [[CrossRef](#)]
85. Niu, T.; Lv, C.; Yi, G.; Tang, H.; Gong, C.; Niu, S. Therapeutic Effect of Medical Ozone on Lumbar Disc Herniation. *Med. Sci. Monit.* **2018**, *24*, 1962–1969. [[CrossRef](#)]
86. O'Neill, T.W.; McCabe, P.S.; McBeth, J. Update on the epidemiology, risk factors and disease outcomes of osteoarthritis. *Best Pract. Res. Clin. Rheumatol.* **2018**, *32*, 312–326. [[CrossRef](#)]
87. Vos, T.; Allen, C.; Arora, M.; Barber, R.M.; Bhutta, Z.A.; Brown, A.; Liang, X.; Kawashima, T.; Coggeshall, M. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. *Lancet* **2015**, *386*, 743–800. [[CrossRef](#)]
88. Lepetsos, P.; Papavassiliou, A.G. ROS/oxidative stress signaling in osteoarthritis. *Biochim. Biophys. Acta—Mol. Basis Dis.* **2016**, *1862*, 576–591. [[CrossRef](#)]
89. Jiang, C.; Luo, P.; Li, X.; Liu, P.; Li, Y.; Xu, J. Nrf2/ARE is a key pathway for curcumin-mediated protection of TMJ chondrocytes from oxidative stress and inflammation. *Cell Stress Chaperon* **2020**, *25*, 395–406. [[CrossRef](#)]

90. de Sire, A.; Marotta, N.; Marinaro, C.; Curci, C.; Invernizzi, M.; Ammendolia, A. Role of Physical Exercise and Nutraceuticals in Modulating Molecular Pathways of Osteoarthritis. *Int. J. Mol. Sci.* **2021**, *22*, 5722. [[CrossRef](#)]
91. Fernández-Cuadros, M.E.; Pérez-Moro, O.S.; Albaladejo-Florin, M.J.; Alava-Rabasa, S. El ozono intraarticular modula la inflamación, mejora el dolor, la rigidez, la función y tiene un efecto anabólico sobre la artrosis de rodilla: Estudio cuasi-experimental prospectivo tipo antes-después, 115 pacientes. *Rev. Soc. Esp. Dolor* **2020**, *27*, 78–88. [[CrossRef](#)]
92. Rankothgedera, S.; Atukorala, I.; Fernando, C.; Munidasa, D.; Wijayarathne, L.; Udagama, P. A potential diagnostic serum immunological marker panel to differentiate between primary and secondary knee osteoarthritis. *PLoS ONE* **2021**, *16*, e0257507. [[CrossRef](#)]
93. Chow, Y.Y.; Chin, K.-Y. The Role of Inflammation in the Pathogenesis of Osteoarthritis. *Mediat. Inflamm.* **2020**, *2020*, 8293921. [[CrossRef](#)]
94. Vincent, T.L. Mechanoflammation in osteoarthritis pathogenesis. *Semin. Arthritis Rheum.* **2019**, *49*, S36–S38. [[CrossRef](#)]
95. Kraus, V.B.; Karsdal, M.A. Osteoarthritis: Current Molecular Biomarkers and the Way Forward. *Calcif. Tissue Res.* **2021**, *109*, 329–338. [[CrossRef](#)]
96. Bar-Or, D.; Rael, L.; Thomas, G.W.; Brody, E.N. Inflammatory Pathways in Knee Osteoarthritis: Potential Targets for Treatment. *Curr. Rheumatol. Rev.* **2015**, *11*, 50–58. [[CrossRef](#)]
97. Wang, M.-N.; Liu, L.; Zhao, L.-P.; Yuan, F.; Fu, Y.-B.; Xu, X.-B.; Li, B. Research of inflammatory factors and signaling pathways in knee osteoarthritis. *Zhongguo Gu Shang* **2020**, *33*, 388–392. [[PubMed](#)]
98. Costa, T.; Rodrigues-Manica, S.; Lopes, C.; Gomes, J.; Marona, J.; Falcao, S.; Branco, J. Ozonoterapia na Osteoartrose do Joelho: Revisão Sistemática. *Acta Méd. Port.* **2018**, *31*, 576–580. [[CrossRef](#)]
99. Sconza, C.; Leonardi, G.; Kon, E.; Respizzi, S.; Massazza, G.; Marcacci, M.; Di Matteo, B. Oxygen-ozone therapy for the treatment of low back pain: A systematic review of randomized controlled trials. *Eur. Rev. Med. Pharmacol. Sci.* **2021**, *25*, 6034–6046. [[CrossRef](#)]
100. Barbosa, L.T.; Rodrigues, C.F.D.S.; De Andrade, R.R.; Barbosa, F.T. The effectiveness of percutaneous injections of ozonotherapy in low back pain. *Rev. Assoc. Méd. Bras.* **2020**, *66*, 1146–1151. [[CrossRef](#)]
101. Hashemi, M.; Khameneh, S.M.H.; Dadkhah, P.; Mohajerani, S.A. Effect of Intraarticular injection of ozone on inflammatory cytokines in knee osteoarthritis. *J. Cell. Mol. Anesth.* **2017**, *2*, 37–42.
102. Sconza, C.; Braghetto, G.; Respizzi, S.; Morengi, E.; Kon, E.; Di Matteo, B. Ultrasound-guided periradicular oxygen-ozone injections as a treatment option for low back pain associated with sciatica. *Int. Orthop.* **2021**, *45*, 1239–1246. [[CrossRef](#)] [[PubMed](#)]
103. Iorio, G.C.; Ammendolia, A.; Marotta, N.; Ricardi, U.; de Sire, A. A bond between rheumatic diseases and cancer in the elderly: The interleukin-6 pathway. *Int. J. Rheum. Dis.* **2021**, *24*, 1317–1320. [[CrossRef](#)] [[PubMed](#)]
104. Higashi, Y.; Sukhanov, S.; Anwar, A.; Shai, S.-Y.; Delafontaine, P. Aging, Atherosclerosis, and IGF-1. *J. Gerontol. Ser. A* **2012**, *67*, 626–639. [[CrossRef](#)] [[PubMed](#)]
105. Tumolo, M.R.; Panico, A.; De Donno, A.; Mincaroni, P.; Leo, C.G.; Guarino, R.; Bagordo, F.; Serio, F.; Idolo, A.; Grassi, T.; et al. The expression of microRNAs and exposure to environmental contaminants related to human health: A review. *Int. J. Environ. Health Res.* **2020**, *32*, 332–354. [[CrossRef](#)]
106. Bromberg, P.A. Mechanisms of the acute effects of inhaled ozone in humans. *Biochim. Biophys. Acta—Gen. Subj.* **2016**, *1860*, 2771–2781. [[CrossRef](#)]
107. Arancibia, S.E.; Zimbron, L.F.H.; Martinez, A.E.R.; Maldonado, P.D.; Perez, G.E.; Parada, M.E. Oxidative stress-dependent changes in immune responses and cell death in the substantia nigra after ozone exposure in rat. *Front. Aging Neurosci.* **2015**, *7*, 65. [[CrossRef](#)]
108. Huth, K.; Saugel, B.; Jakob, F.; Cappello, C.; Quirling, M.; Paschos, E.; Ern, K.; Hickel, R.; Brand, K. Effect of Aqueous Ozone on the NF- κ B System. *J. Dent. Res.* **2007**, *86*, 451–456. [[CrossRef](#)] [[PubMed](#)]
109. Renate, V.H. Chronic inflammatory processes and the low-dose ozone concept based on the International guidelines of medical ozone: Signal transduction and Bioregulation through «Ozone peroxides» as second Messenger molecules. *Медицинский Альманах* **2013**, *3*, 33.
110. Zhang, C.; Ma, S.; Zhao, X.; Wen, B.; Sun, P.; Fu, Z. Upregulation of antioxidant and autophagy pathways via NRF2 activation protects spinal cord neurons from ozone damage. *Mol. Med. Rep.* **2021**, *23*, 428. [[CrossRef](#)]
111. Delgado-Roche, L.; Riera-Romo, M.; Mesta, F.; Hernández-Matos, Y.; Barrios, J.M.; Martínez-Sánchez, G.; Al-Dalaien, S.M. Medical ozone promotes Nrf2 phosphorylation reducing oxidative stress and pro-inflammatory cytokines in multiple sclerosis patients. *Eur. J. Pharmacol.* **2017**, *811*, 148–154. [[CrossRef](#)]
112. Zeng, J.; Lei, L.; Zeng, Q.; Yao, Y.; Wu, Y.; Li, Q.; Gao, L.; Du, H.; Xie, Y.; Huang, J.; et al. Ozone Therapy Attenuates NF- κ B-Mediated Local Inflammatory Response and Activation of Th17 Cells in Treatment for Psoriasis. *Int. J. Biol. Sci.* **2020**, *16*, 1833–1845. [[CrossRef](#)] [[PubMed](#)]
113. Zhang, W.; Wang, F.; Zhang, L.; Sun, T.; Fu, Z. Intrathecal injection of ozone alleviates CCI-induced neuropathic pain via the GluR6-NF- κ B/p65 signalling pathway in rats. *Mol. Med. Rep.* **2021**, *23*, 231. [[CrossRef](#)] [[PubMed](#)]
114. Babaei-Ghazani, A.; Najarzadeh, S.; Mansoori, K.; Forogh, B.; Madani, S.P.; Ebadi, S.; Fadavi, H.R.; Eftekharsadat, B. The effects of ultrasound-guided corticosteroid injection compared to oxygen–ozone (O₂–O₃) injection in patients with knee osteoarthritis: A randomized controlled trial. *Clin. Rheumatol.* **2018**, *37*, 2517–2527. [[CrossRef](#)] [[PubMed](#)]

115. Hedayatabad, J.J.; Kachooei, A.R.; Chaharjouy, N.T.; Vaziri, N.; Mehrad-Majd, H.; Emadzadeh, M.; Abolghasemian, M.; Ebrahimzadeh, M.H. The Effect of Ozone (O₃) versus Hyaluronic Acid on Pain and Function in Patients with Knee Osteoarthritis: A Systematic Review and Meta-Analysis. *Arch. Bone Jt. Surg* **2020**, *8*, 343–354.
116. Hashemi, M.; Taheri, M.; Dadkhah, P.; Hassani, H.; Ataie, M.; Ghasemi, M.; Pourhoseingholi, M.A.; Solhpour, A. Comparison of Two Different Ozone Injection Sites for Knee Osteoarthritis, Tibio-femoral Joint versus Supra-patellar Recess: An Open Randomized Clinical Trial. *J. Pharm. Res. Int.* **2020**, *32*, 37–49. [[CrossRef](#)]
117. Raeissadat, S.A.; Hosseini, P.G.; Bahrami, M.H.; Roghani, R.S.; Fathi, M.; Ahangar, A.G.; Darvish, M. The comparison effects of intra-articular injection of Platelet Rich Plasma (PRP), Plasma Rich in Growth Factor (PRGF), Hyaluronic Acid (HA), and ozone in knee osteoarthritis: A one year randomized clinical trial. *BMC Musculoskelet. Disord.* **2021**, *22*, 134. [[CrossRef](#)]
118. Duymus, T.M.; Mutlu, D.T.; Dernek, B.; Komur, B.; Aydogmus, S.; Kesiktas, F.N. Choice of intra-articular injection in treatment of knee osteoarthritis: Platelet-rich plasma, hyaluronic acid or ozone options. *Knee Surg. Sports Traumatol. Arthrosc.* **2016**, *25*, 485–492. [[CrossRef](#)]
119. Haydt, R.; Boyle, B.; Meyers, M.; Weissberg, S.; Dyrli, K. Comparison of Platelet Rich Plasma and Oxygen Ozone Injections for Knee Osteoarthritis: A Systematic Review. *Arch. Phys. Med. Rehabil.* **2019**, *100*, e149. [[CrossRef](#)]
120. Raeissadat, S.A.; Tabibian, E.; Rayegani, S.M.; Rahimi-Dehgolan, S.; Babaei-Ghazani, A. An investigation into the efficacy of intra-articular ozone (O₂-O₃) injection in patients with knee osteoarthritis: A systematic review and meta-analysis. *J. Pain Res.* **2018**, *11*, 2537–2550. [[CrossRef](#)]
121. Cardelli, R.; de Santis, F.; Dall'Olio, M.; Leonardi, M. Osteoarthritis of the hip treated by intra-articular infiltration of oxygen-ozone and hyaluronic acid (Hyalubrix®). Preliminary results. *Int. J. Ozone Ther.* **2008**, *7*, 66–69.
122. Tartari, A.P.S.; Moreira, F.F.; Pereira, M.C.D.S.; Carraro, E.; Cidral-Filho, F.J.; Salgado, A.I.; Kerppers, I.I. Anti-inflammatory Effect of Ozone Therapy in an Experimental Model of Rheumatoid Arthritis. *Inflammation* **2020**, *43*, 985–993. [[CrossRef](#)]
123. Saraiva, L.; Konzen, V.D.M.; Batista, J.S.; Jorge, M.S.G.; Garcia, G.S.; Wibelinger, L.M. Treatment of Rheumatoid Arthritis with Ozone Therapy: Systematic Review. *Temas Saúde* **2020**, *20*, 4–8. [[CrossRef](#)]
124. Rajaiah, R.; Puttabatappa, M.; Polumuri, S.K.; Moudgil, K.D. Interleukin-27 and Interferon- γ Are Involved in Regulation of Autoimmune Arthritis. *J. Biol. Chem.* **2011**, *286*, 2817–2825. [[CrossRef](#)] [[PubMed](#)]
125. Fernández, O.S.L.; Viebahn-Haensler, R.; Cabreja, G.L.; Espinosa, I.S.; Matos, Y.H.; Roche, L.D.; Santos, B.T.; Oru, G.T.; Vega, J.C.P. Medical ozone increases methotrexate clinical response and improves cellular redox balance in patients with rheumatoid arthritis. *Eur. J. Pharmacol.* **2016**, *789*, 313–318. [[CrossRef](#)] [[PubMed](#)]
126. Scassellati, C.; Galoforo, A.C.; Bonvicini, C.; Esposito, C.; Ricevuti, G. Ozone: A natural bioactive molecule with antioxidant property as potential new strategy in aging and in neurodegenerative disorders. *Ageing Res. Rev.* **2020**, *63*, 101138. [[CrossRef](#)]
127. Zeng, J.; Tang, Z.; Zhang, Y.; Tong, X.; Dou, J.; Gao, L.; Ding, S.; Lu, J. Ozonated autohemotherapy elevates PPAR- γ expression in CD4+ T cells and serum HDL-C levels, a potential immunomodulatory mechanism for treatment of psoriasis. *Am. J. Transl. Res.* **2021**, *13*, 349–359.
128. Antonioli, L.; Blandizzi, C.; Pacher, P.; Haskó, G. The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases. *Pharmacol. Rev.* **2019**, *71*, 345–382. [[CrossRef](#)]
129. Ayers, N.B.; Sun, C.-M.; Chen, S.-Y. Transforming growth factor- β signaling in systemic sclerosis. *J. Biomed. Res.* **2017**, *32*, 3–12.
130. Yagci, I.; Kenis-Coskun, O.; Ozsoy, T.; Ozen, G.; Direskeneli, H. Increased stiffness of median nerve in systemic sclerosis. *BMC Musculoskelet. Disord.* **2017**, *18*, 434. [[CrossRef](#)] [[PubMed](#)]
131. de Sire, A.; Curci, C.; Ferrara, M.; Losco, L.; Spalek, R.; Cisari, C.; Invernizzi, M.; Solaro, C. Efficacy of kinesio taping on hand functioning in patients with mild carpal tunnel syndrome. A double-blind randomized controlled trial. *J. Hand Ther.* **2021**, in press. [[CrossRef](#)]
132. Elawamy, A.; Hassanien, M.; Talaat, E.A.; Ali, A.M.; Roushdy, A.S.I.; Kamel, E.Z. Intra-Carpal Injection of Ozone versus Methylprednisolone in Carpal Tunnel Syndrome of Systemic Sclerosis Patients: A Randomized Single-Blind Clinical Trial. *Pain Phys.* **2021**, *24*, E453–E458. [[CrossRef](#)]
133. Rascaroli, M.W.; Borghi, B.; Rascaroli, A.; Travagli, V. Ozone therapy in idiopathic carpal tunnel syndrome. Biochemical, neurophysiological and clinical aspects. *J. Ozone Ther.* **2018**, *2*, 11286. [[CrossRef](#)]
134. Rascaroli, M.; Borghi, B. Ozone Therapy in Idiopathic Carpal Tunnel Syndrome. Biochemical, Neurophysiological and Clinical Aspects. *J. Ozone Ther.* **2019**, *3*, 49–50. [[CrossRef](#)]
135. Bahrami, M.H.; Raeissadat, S.A.; Nezamabadi, M.; Hojjati, F.; Rahimi-Dehgolan, S. Interesting effectiveness of ozone injection for carpal tunnel syndrome treatment: A randomized controlled trial. *Orthop. Res. Rev.* **2019**, *11*, 61–67. [[CrossRef](#)] [[PubMed](#)]
136. Marotta, N.; Demeco, A.; Marinario, C.; Moggio, L.; Pino, I.; Barletta, M.; Petraroli, A.; Ammendolia, A. Comparative Effectiveness of Orthoses for Thumb Osteoarthritis: A Systematic Review and Network Meta-analysis. *Arch. Phys. Med. Rehabil.* **2021**, *102*, 502–509. [[CrossRef](#)] [[PubMed](#)]
137. Yamanaka, Y.; Gingery, A.; Oki, G.; Zhao, C.; Amadio, P.C.; Yang, T.-H. Blocking fibrotic signaling in fibroblasts from patients with carpal tunnel syndrome. *J. Cell. Physiol.* **2017**, *233*, 2067–2074. [[CrossRef](#)]
138. Yang, T.-H.; Gingery, A.; Thoreson, A.R.; Larson, D.R.; Zhao, C.; Amadio, P.C. Triamcinolone Acetonide affects TGF- β signaling regulation of fibrosis in idiopathic carpal tunnel syndrome. *BMC Musculoskelet. Disord.* **2018**, *19*, 342. [[CrossRef](#)]
139. Dehlin, M.; Jacobsson, L.; Roddy, E. Global epidemiology of gout: Prevalence, incidence, treatment patterns and risk factors. *Nat. Rev. Rheumatol.* **2020**, *16*, 380–390. [[CrossRef](#)]

140. Guillén, A.G.; Karu, L.T.; Singh, J.A.; Dalbeth, N. Gender and Ethnic Inequities in Gout Burden and Management. *Rheum. Dis. Clin. N. Am.* **2020**, *46*, 693–703. [[CrossRef](#)]
141. Bilge, A.; Tüysüz, M.; Öztürk, Ö.; Adali, Y.; Eroğlu, H.A.; Makav, M.; Uslu, G.A.; Tiskaoglu, R. Deneysel Olarak Gut Oluşturulmuş Ratlarda Ozon Terapinin Etkisi. *Kafkas Univ. Vet. Fak. Derg.* **2019**, *25*, 245–249. [[CrossRef](#)]
142. Abdullah, D.M.; Kabil, S.L. Ozone Therapy Alleviates Monosodium Urate Induced Acute Gouty Arthritis in Rats Through Inhibition of NLRP3 Inflammasome. *Curr. Drug Ther.* **2021**, *16*, 345–353. [[CrossRef](#)]
143. Saruhanoğlu, A.; Gökçen-Röhlig, B.; Saruhanoğlu, C.; Öngül, D.; Koray, M. Frequency of temporomandibular disorder signs and symptoms among call center employees. *CRANIO J. Craniomandib. Pract.* **2017**, *35*, 244–249. [[CrossRef](#)] [[PubMed](#)]
144. Rongo, R.; Ekberg, E.; Nilsson, I.; Al-Khotani, A.; Alstergren, P.; Conti, P.C.R.; Durham, J.; Goulet, J.; Hirsch, C.; Kalaykova, S.I.; et al. Diagnostic criteria for temporomandibular disorders (DC/TMD) for children and adolescents: An international Delphi study—Part 1—Development of Axis I. *J. Oral Rehabil.* **2021**, *48*, 836–845. [[CrossRef](#)] [[PubMed](#)]
145. Steenks, M.; Türp, J.; De Wijer, A. Reliability and Validity of the Diagnostic Criteria for Temporomandibular Disorders Axis I in Clinical and Research Settings: A Critical Appraisal. *J. Oral Facial Pain Headache* **2018**, *32*, 7–18. [[CrossRef](#)] [[PubMed](#)]
146. Gauer, R.L.; Semidey, M.J. Diagnosis and treatment of temporomandibular disorders. *Am. Fam. Phys.* **2015**, *91*, 378–386.
147. Wieckiewicz, M.; Smardz, J.; Martynowicz, H.; Wojakowska, A.; Mazur, G.; Winocur, E. Distribution of temporomandibular disorders among sleep bruxers and non-bruxers—A polysomnographic study. *J. Oral Rehabil.* **2020**, *47*, 820–826. [[CrossRef](#)]
148. Manfredini, D.; Guarda-Nardini, L.; Winocur, E.; Piccotti, F.; Ahlberg, J.; Lobbezoo, F. Research diagnostic criteria for temporomandibular disorders: A systematic review of axis I epidemiologic findings. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontology.* **2011**, *112*, 453–462. [[CrossRef](#)]
149. Talaat, W.M.; Adel, O.I.; Al Bayatti, S. Prevalence of temporomandibular disorders discovered incidentally during routine dental examination using the Research Diagnostic Criteria for Temporomandibular Disorders. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol.* **2018**, *125*, 250–259. [[CrossRef](#)]
150. Slade, G.; Ohrbach, R.; Greenspan, J.; Fillingim, R.; Bair, E.; Sanders, A.; Dubner, R.; Diatchenko, L.; Meloto, C.; Smith, S.; et al. Painful Temporomandibular Disorder: Decade of Discovery from OPPERA Studies. *J. Dent. Res.* **2016**, *95*, 1084–1092. [[CrossRef](#)]
151. Karlsson, O.; Karlsson, T.; Pauli, N.; Andréll, P.; Finizia, C. Jaw exercise therapy for the treatment of trismus in head and neck Cancer: A prospective three-year follow-up study. *Support. Care Cancer* **2021**, *29*, 3793–3800. [[CrossRef](#)]
152. Özalp, Ö.; Yıldırım, N.; Sindel, A.; Altay, M.A.; Kişnişçi, R.Ş. Evaluation of the Short-Term Efficacy of Transdermal Ozone Therapy in Turkish Patients with Internal Derangement of the Temporomandibular Joint. *Pesqui. Bras. Odontopediatr. Clín. Integr.* **2019**, *19*, 1–10. [[CrossRef](#)]
153. Fillingim, R.; Ohrbach, R.; Greenspan, J.; Sanders, A.; Rathnayaka, N.; Maixner, W.; Slade, G. Associations of Psychologic Factors with Multiple Chronic Overlapping Pain Conditions. *J. Oral Facial Pain Headache* **2020**, *34*, s85–s100. [[CrossRef](#)]
154. A Review the Relationship of Bruxism with Temporomandibular Disorders in Children. *Syst. Rev. Pharm.* **2020**, *11*, 136–142. [[CrossRef](#)]
155. Seo, H.; Jung, B.; Yeo, J.; Kim, K.-W.; Cho, J.-H.; Lee, Y.J.; Ha, I.-H. Healthcare utilisation and costs for temporomandibular disorders: A descriptive, cross-sectional study. *BMJ Open* **2020**, *10*, e036768. [[CrossRef](#)] [[PubMed](#)]
156. Okeson, J. *Management of Temporomandibular Disorder and Occlusion*, 4th ed.; Elsevier: Mosby, MO, USA, 1998; pp. 349–380.
157. Glaros, A.G.; Tabacchi, K.N.; Glass, E.G. Effect of parafunctional clenching on TMD pain. *J. Orofac. Pain* **1998**, *12*, 145–152. [[PubMed](#)]
158. Fillingim, R.B.; Ohrbach, R.; Greenspan, J.; Knott, C.; Diatchenko, L.; Dubner, R.; Bair, E.; Baraian, C.; Mack, N.; Slade, G.D.; et al. Psychological Factors Associated With Development of TMD: The OPPERA Prospective Cohort Study. *J. Pain* **2013**, *14*, T75–T90. [[CrossRef](#)] [[PubMed](#)]
159. Dıraçoğlu, D.; Yıldırım, N.K.; Saral, I.; Özkan, M.; Karan, A.; Özkan, S.; Aksoy, C. Temporomandibular dysfunction and risk factors for anxiety and depression. *J. Back Musculoskelet. Rehabil.* **2016**, *29*, 487–491. [[CrossRef](#)]
160. Kellesarian, S.V.; Al-Kheraif, A.A.; Vohra, F.; Ghanem, A.; Malmstrom, H.; Romanos, G.E.; Javed, F. Cytokine profile in the synovial fluid of patients with temporomandibular joint disorders: A systematic review. *Cytokine* **2016**, *77*, 98–106. [[CrossRef](#)]
161. de Bont, L.G.; Stegenga, B. Pathology of temporomandibular joint internal derangement and osteoarthritis. *Int. J. Oral Maxillofac. Surg.* **1993**, *22*, 71–74. [[CrossRef](#)]
162. Sandler, N.; Buckley, M.J.; Cillo, J.; Braun, T.W. Correlation of inflammatory cytokines with arthroscopic findings in patients with temporomandibular joint internal derangements. *J. Oral Maxillofac. Surg.* **1998**, *56*, 534–543. [[CrossRef](#)]
163. Tanaka, A.; Kumagai, S.; Kawashiri, S.; Takatsuka, S.; Nakagawa, K.; Yamamoto, E.; Matsumoto, N. Expression of matrix metalloproteinase-2 and -9 in synovial fluid of the temporomandibular joint accompanied by anterior disc displacement. *J. Oral Pathol. Med.* **2001**, *30*, 59–64. [[CrossRef](#)]
164. Yoshida, K.; Takatsuka, S.; Tanaka, A.; Hatada, E.; Nakamura, H.; Nakagawa, K.; Okada, Y. Aggrecanase analysis of synovial fluid of temporomandibular joint disorders. *Oral Dis.* **2005**, *11*, 299–302. [[CrossRef](#)]
165. Lv, X.; Li, Q.; Wu, S.; Sun, J.; Zhang, M.; Chen, Y.-J. Psychological stress alters the ultrastructure and increases IL-1 β and TNF- α in mandibular condylar cartilage. *Braz. J. Med. Biol. Res.* **2012**, *45*, 968–976. [[CrossRef](#)] [[PubMed](#)]
166. Ulmner, M.; Sugars, R.; Naimi-Akbar, A.; Suslu, S.; Reseland, J.E.; Kruger-Weiner, C.; Lund, B. Synovial tissue cytokine profile in disc displacement of the temporomandibular joint. *J. Oral Rehabil.* **2020**, *47*, 1202–1211. [[CrossRef](#)] [[PubMed](#)]

167. Son, C.; Park, Y.K.; Park, J.W. Long-term evaluation of temporomandibular disorders in association with cytokine and autoantibody status in young women. *Cytokine* **2021**, *144*, 155551. [[CrossRef](#)] [[PubMed](#)]
168. Deregibus, A.; Ferrillo, M.; Grazia Piancino, M.; Chiara Domini, M.; de Sire, A.; Castroflorio, T. Are occlusal splints effective in reducing myofascial pain in patients with muscle-related temporomandibular disorders? A randomized-controlled trial. *Turk. J. Phys. Med. Rehabil.* **2021**, *67*, 32–40. [[CrossRef](#)] [[PubMed](#)]
169. Vrbanović, E.; Alajbeg, I.Z. Long-term Effectiveness of Occlusal Splint Therapy Compared to Placebo in Patients with Chronic Temporomandibular Disorders. *Acta Stomatol. Croat.* **2019**, *53*, 195–206. [[CrossRef](#)] [[PubMed](#)]
170. Michelotti, A.; Iodice, G.; Vollaro, S.; Steenks, M.H.; Farella, M. Evaluation of the short-term effectiveness of education versus an occlusal splint for the treatment of myofascial pain of the jaw muscles. *J. Am. Dent. Assoc.* **2012**, *143*, 47–53. [[CrossRef](#)] [[PubMed](#)]
171. Armijo-Olivo, S.; Pitance, L.; Singh, V.; Neto, F.; Thie, N.; Michelotti, A. Effectiveness of Manual Therapy and Therapeutic Exercise for Temporomandibular Disorders: Systematic Review and Meta-Analysis. *Phys. Ther.* **2016**, *96*, 9–25. [[CrossRef](#)]
172. Ketabi, M.A.; Sabzijati, M. Effect of low-level laser on controlling temporomandibular disorders. *Rev. Latinoam. Hipertens.* **2020**, *15*, 138–143.
173. Fertout, A.; Manière-Ezvan, A.; Lupi, L.; Ehrmann, E. Management of temporomandibular disorders with transcutaneous electrical nerve stimulation: A systematic review. *CRANIO J. Craniomandib. Pract.* **2019**, *9*, 1–12. [[CrossRef](#)] [[PubMed](#)]
174. Yamaner, F.E.; Celakil, T.; Roehlig, B.G. Comparison of the efficiency of two alternative therapies for the management of temporomandibular disorders. *CRANIO J. Craniomandib. Pract.* **2020**, *15*, 1–10. [[CrossRef](#)]
175. Oshaghi, S.; Haghighat, S. Effectiveness of ozone injection therapy in temporomandibular disorders. *Adv. Biomed. Res.* **2020**, *9*, 73. [[CrossRef](#)]
176. Ávila-Curiel, B.X.; Gómez-Aguirre, J.N.; Gijón-Soriano, A.L.; Acevedo-Mascarúa, A.E.; Argueta-Figueroa, L.; Torres-Rosas, R. Intervenciones complementarias para el tratamiento de dolor en pacientes con alteraciones temporomandibulares: Una revisión sistemática. *Rev. Int. Acupunt.* **2020**, *14*, 151–159. [[CrossRef](#)]
177. Ferrillo, M.; Ammendolia, A.; Paduano, S.; Calafiore, D.; Marotta, N.; Migliario, M.; Fortunato, L.; Giudice, A.; Michelotti, A.; de Sire, A. Efficacy of rehabilitation on reducing pain in muscle-related temporomandibular disorders: Systematic review and meta-analysis of randomized controlled trials. *J. Back Musculoskelet. Rehabil.* **2022**, *1*, 1–16. [[CrossRef](#)]
178. Celakil, T.; Muric, A.; Roehlig, B.G.; Evlioglu, G.; Keskin, H. Effect of high-frequency bio-oxidative ozone therapy for masticatory muscle pain: A double-blind randomised clinical trial. *J. Oral Rehabil.* **2017**, *44*, 442–451. [[CrossRef](#)]
179. Celakil, T.; Muric, A.; Roehlig, B.G.; Evlioglu, G. Management of pain in TMD patients: Bio-oxidative ozone therapy versus occlusal splints. *CRANIO J. Craniomandib. Pract.* **2019**, *37*, 85–93. [[CrossRef](#)]
180. Daif, E.T. Role of intra-articular ozone gas injection in the management of internal derangement of the temporomandibular joint. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol.* **2012**, *113*, e10–e14. [[CrossRef](#)]
181. Doğan, M.; Doğan, D.Ö.; Duger, C.; Kol, I.Ö.; Akpınar, A.; Mutaf, B.; Akar, T. Effects of High-Frequency Bio-Oxidative Ozone Therapy in Temporomandibular Disorder-Related Pain. *Med. Princ. Pract.* **2014**, *23*, 507–510. [[CrossRef](#)]